Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2000 Nov 28;163(11):1441-8.

Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality

F L Paradiso-Hardy  1 , C M Angelo, K L Lanctôt, E A Cohen
Affiliations
Meta-Analysis

Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality

F L Paradiso-Hardy et al. CMAJ. .

Abstract

Background: Several rare, potentially fatal types of hematologic dyscrasia, such as agranulocytosis, aplastic anemia, neutropenia, pancytopenia, thrombocytopenia and thrombotic thrombocytopenic purpura (TTP), have been associated with ticlopidine therapy. The extent to which ticlopidine is the causative factor has not been addressed quantitatively.

Methods: We identified 211 published case reports of hematologic dyscrasia associated with ticlopidine therapy from a MEDLINE search. We analyzed the 91 reports that could be evaluated, using the Bayesian Adverse Reaction Diagnostic Instrument to calculate the posterior probability that ticlopidine caused the hematologic dyscrasia based on epidemiologic and clinical trial data (prior odds) and case information (likelihood ratio).

Results: The median posterior probability values (and range) for agranulocytosis, aplastic anemia, neutropenia, pancytopenia, thrombocytopenia and TTP were 0.95 (0.53-0.98), 0.81 (0.57-0.93), 0.86 (0.75-0.96), 0.78 (0.61-0.89), 0.74 (0-0.92) and 1.0 (0.33-1.00) respectively. The posterior probability was 0.75 or greater in 82 (90%) of the case reports.

Interpretation: This systematic analysis provides stronger evidence to implicate ticlopidine as the causative factor in the various types of hematologic dyscrasia in most published case reports.

PubMed Disclaimer

Figures

None
Fig. 1: Posterior probabilities for 91 case reports of hematologic dyscrasia associated with ticlopidine therapy. The posterior probability was 0.75 or greater (indicating a probability of at least 75% that ticlopidine caused the dyscrasia) (dashed line) in 82 (90%) of the case reports. TTP = thrombotic thrombocytopenic purpura.
See this image and copyright information in PMC

Comment in

References

    1. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20. - PubMed
    1. Hass W, Easton D, Adams H, Pryse-Phillips W, Molony B, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-7. - PubMed
    1. Balsano F, Rizzon P, Violi F. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 1990;82:17-26. - PubMed
    1. Limet R, David J, Maggotteax P. Prevention of aorta-coronary bypass graft occlusion C beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987;94:773-83. - PubMed
    1. Becquemin JP, for the Étude de la Ticlopidine après Pontage Fémoro-Poplite and the Association Universitaire de Recherche en Chirurgie. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 1997;337:1726-31. - PubMed

Publication types

Substances